JP2015506359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506359A5 JP2015506359A5 JP2014551233A JP2014551233A JP2015506359A5 JP 2015506359 A5 JP2015506359 A5 JP 2015506359A5 JP 2014551233 A JP2014551233 A JP 2014551233A JP 2014551233 A JP2014551233 A JP 2014551233A JP 2015506359 A5 JP2015506359 A5 JP 2015506359A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- acetaminophen
- administered
- active ingredients
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 27
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229960005489 paracetamol Drugs 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 7
- 230000003111 delayed effect Effects 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 230000000202 analgesic effect Effects 0.000 claims 3
- 229940124538 antidiuretic agent Drugs 0.000 claims 3
- 229940124575 antispasmodic agent Drugs 0.000 claims 3
- 239000000812 cholinergic antagonist Substances 0.000 claims 3
- 239000003149 muscarinic antagonist Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 239000003160 antidiuretic agent Substances 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- 229960000396 atropine Drugs 0.000 claims 2
- 229960002677 darifenacin Drugs 0.000 claims 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 230000027939 micturition Effects 0.000 claims 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 2
- 229960004270 nabumetone Drugs 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- 229960003940 naproxen sodium Drugs 0.000 claims 2
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 claims 2
- 229960005434 oxybutynin Drugs 0.000 claims 2
- 229960003855 solifenacin Drugs 0.000 claims 2
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
- 230000002686 anti-diuretic effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 229940074045 glyceryl distearate Drugs 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/343,349 US20120141554A1 (en) | 2010-07-08 | 2012-01-04 | Delayed release formulation for reducing the frequency of urination and method of use thereof |
| US13/343,349 | 2012-01-04 | ||
| US13/423,949 US8236856B2 (en) | 2010-07-08 | 2012-03-19 | Delayed release formulation for reducing the frequency of urination and method of use thereof |
| US13/423,949 | 2012-03-19 | ||
| US13/487,343 US20120237574A1 (en) | 2010-07-08 | 2012-06-04 | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| US13/487,343 | 2012-06-04 | ||
| PCT/US2012/051859 WO2013103389A1 (en) | 2012-01-04 | 2012-08-22 | Delayed-release formulation for reducing the frequency of urination and method of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017017179A Division JP2017122091A (ja) | 2012-01-04 | 2017-02-02 | 排尿頻度を減少させるための遅延放出製剤およびその使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506359A JP2015506359A (ja) | 2015-03-02 |
| JP2015506359A5 true JP2015506359A5 (OSRAM) | 2015-04-23 |
Family
ID=48745354
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551233A Pending JP2015506359A (ja) | 2012-01-04 | 2012-08-22 | 排尿頻度を減少させるための遅延放出製剤およびその使用の方法 |
| JP2017017179A Pending JP2017122091A (ja) | 2012-01-04 | 2017-02-02 | 排尿頻度を減少させるための遅延放出製剤およびその使用の方法 |
| JP2018215136A Pending JP2019055969A (ja) | 2012-01-04 | 2018-11-16 | 排尿頻度を減少させるための遅延放出製剤およびその使用の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017017179A Pending JP2017122091A (ja) | 2012-01-04 | 2017-02-02 | 排尿頻度を減少させるための遅延放出製剤およびその使用の方法 |
| JP2018215136A Pending JP2019055969A (ja) | 2012-01-04 | 2018-11-16 | 排尿頻度を減少させるための遅延放出製剤およびその使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8703184B2 (OSRAM) |
| JP (3) | JP2015506359A (OSRAM) |
| KR (3) | KR20190049928A (OSRAM) |
| AU (1) | AU2012363788B2 (OSRAM) |
| BR (1) | BR112014016550A8 (OSRAM) |
| CA (1) | CA2856673C (OSRAM) |
| IL (1) | IL232711A0 (OSRAM) |
| MX (1) | MX2014008284A (OSRAM) |
| RU (1) | RU2597156C2 (OSRAM) |
| SG (1) | SG11201500410XA (OSRAM) |
| WO (1) | WO2013103389A1 (OSRAM) |
| ZA (1) | ZA201403762B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130323288A1 (en) | 2010-07-08 | 2013-12-05 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
| US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
| US10010514B2 (en) | 2010-07-08 | 2018-07-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
| US10278925B2 (en) * | 2012-01-04 | 2019-05-07 | Wellesley Pharmaceuticals, Llc | Delayed-release formulations, methods of making and use thereof |
| US10105330B2 (en) | 2012-01-04 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Extended, delayed and immediate release formulation method of manufacturing and use thereof |
| US10792326B2 (en) | 2013-06-28 | 2020-10-06 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
| WO2016041036A1 (pt) * | 2014-09-19 | 2016-03-24 | Diffucap Chemobras Química E Farmacéutical Ltda | Combinação farmacêutica contendo um agente analgésico e um agente antiespasmódico |
| US10105328B2 (en) * | 2014-06-06 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
| SG11201610383YA (en) * | 2014-06-06 | 2017-02-27 | Wellesley Pharmaceuticals Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
| KR20180054656A (ko) * | 2015-09-01 | 2018-05-24 | 웰즐리 파마슈티컬스 엘엘씨 | 지연-방출 제형, 제조 방법 및 용도 |
| AU2016317092A1 (en) * | 2015-09-01 | 2018-04-26 | Wellesley Pharmaceuticals, Llc | Extended, delayed and immediate release formulation method of manufacturing and use thereof |
| KR102314838B1 (ko) | 2021-04-01 | 2021-10-19 | 송관권 | 터널 비개착공법 |
| KR102364887B1 (ko) | 2021-06-14 | 2022-02-18 | 송관권 | 터널 비개착 일체식 압입공법 및 그에 적용되는 일체식 가설구조물 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990009168A1 (en) * | 1989-02-16 | 1990-08-23 | National Research Development Corporation | Dispensing device |
| DK0566709T5 (da) * | 1991-09-06 | 2009-05-18 | Ortho Mcneil Janssen Pharm | Præparat indeholdende et tramadolmateriale og acetaminophen og anvendelse deraf |
| US6090856A (en) * | 1997-04-11 | 2000-07-18 | Nippon Shinyaku Co., Ltd. | Remedies for frequent urination and urinary incontinence |
| CA2320193A1 (en) * | 1998-02-10 | 1999-08-19 | Welfide Corporation | Controlled release preparation |
| US7138393B2 (en) * | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| AU7360700A (en) | 1999-09-09 | 2001-04-10 | Androsolutions, Inc. | Methods and compositions for preventing and treating urinary tract disorders |
| BR0113644A (pt) | 2000-08-30 | 2003-07-29 | Lilly Icos Llc | Usos do inibidor de pde5 no tratamento de enxaqueca |
| RU2193401C1 (ru) * | 2001-04-02 | 2002-11-27 | Аль-Шукри Салман Хасунович | Способ лечения гиперактивности мочевого пузыря |
| WO2003029199A1 (en) | 2001-09-28 | 2003-04-10 | Takeda Chemical Industries, Ltd. | Benzene derivatives, process for preparing the same and use thereof |
| JPWO2003043655A1 (ja) * | 2001-11-19 | 2005-03-10 | 小野薬品工業株式会社 | 頻尿の治療剤 |
| WO2003070233A1 (en) * | 2002-02-19 | 2003-08-28 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
| RS20050007A (sr) * | 2002-07-08 | 2007-09-21 | Glaxo Smith Kline Istraživački Centar Zagreb D.O.O., | NOVE NESTEROIDNE-ANTI- INFLAMATORNE SUPSTANCE, KOMPOZICIJE I POSTUPCI ZA NjIHOVU UPOTREBU |
| WO2004007495A1 (ja) | 2002-07-11 | 2004-01-22 | Takeda Pharmaceutical Company Limited | ピロロピリジン誘導体およびその用途 |
| US20050152905A1 (en) * | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
| US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
| DE60319252T2 (de) * | 2002-09-21 | 2009-03-05 | Zhang, Shuyi | Formulierung von acetaminophen und tramadol mit verzögerter freisetzung |
| EP1492519B1 (en) * | 2003-03-21 | 2006-11-15 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators |
| US20040186180A1 (en) * | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
| US8029822B2 (en) | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| DE10356112A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
| EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
| US20080009538A1 (en) * | 2005-03-21 | 2008-01-10 | Phil Skolnick | Methods and compositions for the treatment of urinary incontinence |
| EP1741444A1 (en) * | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| US20080166407A1 (en) | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
| WO2007072503A2 (en) * | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
| WO2007083323A2 (en) | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
| CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| US20090069275A1 (en) | 2006-02-17 | 2009-03-12 | Rocca Jose G | Low flush niacin formulation |
| US20070237816A1 (en) * | 2006-04-06 | 2007-10-11 | David Finkelstein | Acetaminophen formulation for joint pain relief |
| EP2068837A2 (en) | 2006-07-28 | 2009-06-17 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
| CA2661085A1 (en) * | 2006-08-18 | 2008-02-21 | N.V. Organon | Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent |
| US20080057122A1 (en) * | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
| US8399410B2 (en) | 2007-08-06 | 2013-03-19 | Allergan, Inc. | Methods and devices for desmopressin drug delivery |
| US20120064159A1 (en) * | 2009-05-28 | 2012-03-15 | Aptapharma, Inc. | Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen |
| GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| US20120135050A1 (en) | 2010-07-08 | 2012-05-31 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
-
2012
- 2012-08-22 AU AU2012363788A patent/AU2012363788B2/en not_active Ceased
- 2012-08-22 JP JP2014551233A patent/JP2015506359A/ja active Pending
- 2012-08-22 MX MX2014008284A patent/MX2014008284A/es unknown
- 2012-08-22 BR BR112014016550A patent/BR112014016550A8/pt not_active Application Discontinuation
- 2012-08-22 KR KR1020197012474A patent/KR20190049928A/ko not_active Ceased
- 2012-08-22 SG SG11201500410XA patent/SG11201500410XA/en unknown
- 2012-08-22 KR KR1020187005475A patent/KR20180023057A/ko not_active Ceased
- 2012-08-22 WO PCT/US2012/051859 patent/WO2013103389A1/en not_active Ceased
- 2012-08-22 RU RU2014131238/15A patent/RU2597156C2/ru not_active IP Right Cessation
- 2012-08-22 CA CA2856673A patent/CA2856673C/en not_active Expired - Fee Related
- 2012-08-22 KR KR1020147018674A patent/KR20140108674A/ko not_active Ceased
-
2013
- 2013-03-20 US US13/847,940 patent/US8703184B2/en not_active Expired - Fee Related
-
2014
- 2014-02-07 US US14/175,183 patent/US20140154314A1/en not_active Abandoned
- 2014-05-20 IL IL232711A patent/IL232711A0/en unknown
- 2014-05-22 ZA ZA2014/03762A patent/ZA201403762B/en unknown
-
2017
- 2017-02-02 JP JP2017017179A patent/JP2017122091A/ja active Pending
-
2018
- 2018-11-16 JP JP2018215136A patent/JP2019055969A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506359A5 (OSRAM) | ||
| RU2014131238A (ru) | Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения | |
| JP2015503583A5 (OSRAM) | ||
| TN2013000220A1 (en) | Orally disintegrating tablet | |
| NZ588499A (en) | Controlled-release particles with core comprising a weakly basic drug and a controlled-release coating | |
| JP2017019858A5 (OSRAM) | ||
| JP2016522191A (ja) | ロスバスタチンまたはその薬学的に許容可能な塩を含有する膜コーティング層を含む複合製剤 | |
| CN110051642A (zh) | 包含包封于硬胶囊中的多单元球状片剂（must）的复合制剂及其制备方法 | |
| JP2016535773A5 (OSRAM) | ||
| RU2017137643A (ru) | Составы l-орнитин фенилацетата | |
| CN101711752A (zh) | 一种苯并异噁唑类衍生物的控释制剂及其制备方法 | |
| JP2018087217A (ja) | 排尿頻度を減少させるための延長放出製剤およびその使用の方法 | |
| JP2018024693A (ja) | 排尿頻度を減少させるための延長放出製剤およびその使用方法 | |
| RU2014127884A (ru) | Способы лечения сердечно-сосудистого нарушения | |
| CN103784414B (zh) | 一种埃索美拉唑肠溶片及其制备方法 | |
| CN105326837A (zh) | 一种盐酸美金刚缓释-多奈哌齐速释复方胶囊 | |
| JP2014533656A5 (OSRAM) | ||
| CA2797812A1 (en) | Enteric tablet | |
| WO2012144964A1 (en) | Thiocolchicoside, diclofenac and lansoprazole combinations | |
| CN102335155A (zh) | 一种富马酸喹硫平缓释片及其制备方法 | |
| RU2018137323A (ru) | Пероральные фармацевтические композиции никотинамида | |
| CN102058544B (zh) | 非诺贝特酸胆碱盐肠溶缓释微丸的制备方法 | |
| EP3532028A1 (en) | Pharmaceutical compositions comprising a fumaric acid ester and method for the preparation thereof | |
| JP2010024244A5 (OSRAM) | ||
| CN104856971B (zh) | 一种脉冲双释放制剂及其制备方法与应用 |